Tutti gli studi
Attivo ma non reclutanteOSSERVAZIONALE

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

This study, called HEM-POWR, is investigating a medicine called Jivi (damoctocog alfa pegol) for people living with haemophilia A. The main goal is to understand how this treatment is used in everyday situations, how well patients tolerate it over time, and how satisfied both patients and their doctors are with its effects. It's an important step in learning more about the long-term benefits and safety of Jivi, helping to improve care for those with haemophilia A. All ages and genders can potentially take part if they meet certain health criteria, and it focuses on real-world treatment experiences.

A colpo d'occhio

Stato
Attivo ma non reclutante
Sponsor
Bayer
Obiettivo di iscrizione
371
Inizio
21 Oct 2019
Completamento stimato
31 Mar 2027

Di cosa tratta questo studio?

Haemophilia A is a lifelong inherited bleeding disorder where blood doesn't clot properly. This can lead to unexpected and potentially serious bleeding episodes. Treatments like Jivi (damoctocog alfa pegol) are designed to help the blood clot better, reducing these bleeding risks and allowing people to live fuller lives.

This particular study, known as HEM-POWR, aims to gather real-world information about Jivi. Instead of testing a new drug, it focuses on understanding how Jivi works for people who are already using it or are about to start using it in their daily routine. The researchers want to see how effective it is over a longer period, if people experience any side effects, and generally how patients and their doctors feel about the treatment.

The findings from this study will help healthcare professionals and patients make more informed decisions about treatment options for haemophilia A. By looking at how Jivi performs in everyday life, the study contributes to our overall knowledge of managing this condition and ensuring patients receive the best possible care.

Punti chiave

  • The HEM-POWR study looks at Jivi (damoctocog alfa pegol) for haemophilia A.
  • It collects real-world information on how Jivi is used and tolerated.
  • Focuses on patient and doctor satisfaction with the treatment.
  • Aimed at improving long-term understanding of haemophilia A care.
  • Open to all ages and genders with haemophilia A, if criteria are met.

Chi può essere idoneo?

To be part of this study, you would need to have a diagnosis of haemophilia A and have received treatment for it before. You might be eligible if you haven't had issues with 'inhibitors' (where your body fights against the treatment) or if you've had them in the past but have been stable on preventive treatment for at least a year. Importantly, you shouldn't currently have any sign or suspicion of these inhibitors.

Another key requirement is that you are either about to start taking Jivi (damoctocog alfa pegol) or are already taking it, whether that's regularly to prevent bleeds, occasionally when a bleed happens, or on an intermittent basis. You would also need to agree to take part and provide your consent.

There are certain reasons why you might not be able to join. For example, if you're already in another study involving new treatments, or if you have other bleeding disorders apart from haemophilia A. Also, if there are specific medical reasons in the UK preventing you from taking Jivi, or if you're currently receiving treatment to get rid of inhibitors, you would not be able to participate.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I have been diagnosed with Haemophilia A.
  2. I have been treated for Haemophilia A before.
  3. I am starting Jivi (damoctocog alfa pegol) or am already taking it.
  4. I don't currently have complications where my body fights the treatment (inhibitors).
  5. I'm not currently taking part in another study with new treatments.
  6. I'm not receiving special treatment for inhibitors right now.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

This study is designed to observe how Jivi is used in real life, so it mainly involves collecting information about your existing treatment rather than prescribing new tests or specific visits. You would continue to take Jivi as prescribed by your doctor, whether that's regularly, when needed, or occasionally. The study team will gather details about your experience, including how well the medicine works for you and if you have any side effects. This information will likely come from your regular clinic visits and possibly questionnaires about your satisfaction. The total duration of your participation would depend on how long you remain on Jivi as part of your standard care.

Rischi e benefici potenziali

Potential benefits of taking part include contributing valuable real-world information that could improve understanding and care for people with haemophilia A in the future. As you would be receiving Jivi as part of your standard care, the risks are generally those associated with the medicine itself, which your doctor should have already discussed with you. The study itself is mainly about observing and collecting information rather than introducing new medical procedures. You are always free to withdraw from the study at any time without it affecting your medical care.

Locations (29)

  • South Alabama Medical Science Foundation
    Codice postale verificato
    Mobile, Stati Uniti
  • Banner MD Anderson Cancer Center
    Codice postale verificato
    Phoenix, Stati Uniti
  • Università della California, Davis
    Codice postale verificato
    Davis, United States
  • Orthopaedic Hospital DBA Orthopaedic Institute for Children
    Codice postale verificato
    Los Angeles, Stati Uniti
  • The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders
    Codice postale verificato
    Orange, Stati Uniti
  • University of Colorado Hemophilia and Thrombosis Center
    Codice postale verificato
    Aurora, Stati Uniti
  • Georgetown University
    Codice postale verificato
    Washington D.C., Stati Uniti
  • Tulane University
    Codice postale verificato
    New Orleans, Stati Uniti
  • Regents of University of Minnesota
    Codice postale verificato
    Minneapolis, Stati Uniti
  • East Carolina University - Brody School of Medicine
    Codice postale verificato
    Greenville, United States
  • Many locations
    Non verificato
    Multiple Locations, Belgium
  • Many locations
    Non verificato
    Multiple Locations, Brazil

Domande comuni

Qual è l'obiettivo principale di questo studio?

The main goal is to understand how Jivi (damoctocog alfa pegol) is used in day-to-day life by people with haemophilia A, how safe it is long-term, and how happy patients and doctors are with it.

What is Jivi?

Jivi (damoctocog alfa pegol) is a medicine used to treat haemophilia A, helping blood to clot properly.

Do I need to be taking Jivi already to join?

You can either be about to start taking Jivi or already be using it to be eligible for this study.

Will this study give me new medication?

No, this study observes how Jivi is used in standard care; it doesn't provide new, unapproved medication.

What is an 'inhibitor'?

An inhibitor is when your body's immune system stops the haemophilia medicine from working effectively.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.